Tags

Type your tag names separated by a space and hit enter

Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy.

Abstract

The purpose of this study was to test the hypothesis that administration of epigallocatechin-3-gallate (EGCG), a polyphenol present in abundance in widely consumed tea, inhibits cell proliferation, invasion, and angiogenesis in breast cancer patients. EGCG in 400 mg capsules was orally administered three times daily to breast cancer patients undergoing treatment with radiotherapy. Parameters related to cell proliferation, invasion, and angiogenesis were analyzed while blood samples were collected at different time points to determine efficacy of the EGCG treatment. Compared to patients who received radiotherapy alone, those given radiotherapy plus EGCG for an extended time period (two to eight weeks) showed significantly lower serum levels of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and reduced activation of metalloproteinase-9 and metalloproteinase-2 (MMP9/MMP2). Addition of sera obtained from patients treated with combination of radiotherapy and EGCG feeding for 2-8 weeks to in vitro cultures of highly-metastatic human MDA-MB-231 breast cancer cells resulted in the following significant changes: (1) suppression of cell proliferation and invasion; (2) arrest of cell cycles at the G0/G1 phase; (3) reduction of activation of MMP9/MMP2, expressions of Bcl-2/Bax, c-Met receptor, NF-κB, and the phosphorylation of Akt. MDA-MB-231 cells exposed to 5-10 µM EGCG also showed significant augmentation of the apoptosis inducing effects of γ-radiation, concomitant with reduced NF-κB protein level and AKT phosphorylation. These results provide hitherto unreported evidence that EGCG potentiated efficacy of radiotherapy in breast cancer patients, and raise the possibility that this tea polyphenol has potential to be a therapeutic adjuvant against human metastatic breast cancer.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Laboratory of Molecular Pharmacology, School of Pharmacy, Yantai University, Yantai, Shandong Province 264005, China. zhang_zhang6173@yahoo.com.cn

    , , , , , , , , , , , , , , , , , , , ,

    Source

    Current molecular medicine 12:2 2012 Feb pg 163-76

    MeSH

    Administration, Oral
    Adult
    Antineoplastic Agents, Phytogenic
    Apoptosis
    Breast Neoplasms
    Catechin
    Cell Cycle Checkpoints
    Cell Line, Tumor
    Cell Proliferation
    Chemotherapy, Adjuvant
    Enzyme Activation
    Female
    Gene Expression Regulation, Neoplastic
    Hepatocyte Growth Factor
    Humans
    Matrix Metalloproteinase 2
    Matrix Metalloproteinase 9
    Middle Aged
    NF-kappa B
    Neoplasm Invasiveness
    Phosphorylation
    Proto-Oncogene Proteins c-akt
    Proto-Oncogene Proteins c-bcl-2
    Proto-Oncogene Proteins c-met
    Tea
    Vascular Endothelial Growth Factor A
    bcl-2-Associated X Protein

    Pub Type(s)

    Journal Article
    Research Support, N.I.H., Extramural
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    22280355

    Citation

    Zhang, G, et al. "Anti-cancer Activities of Tea Epigallocatechin-3-gallate in Breast Cancer Patients Under Radiotherapy." Current Molecular Medicine, vol. 12, no. 2, 2012, pp. 163-76.
    Zhang G, Wang Y, Zhang Y, et al. Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy. Curr Mol Med. 2012;12(2):163-76.
    Zhang, G., Wang, Y., Zhang, Y., Wan, X., Li, J., Liu, K., ... Wu, E. (2012). Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy. Current Molecular Medicine, 12(2), pp. 163-76.
    Zhang G, et al. Anti-cancer Activities of Tea Epigallocatechin-3-gallate in Breast Cancer Patients Under Radiotherapy. Curr Mol Med. 2012;12(2):163-76. PubMed PMID: 22280355.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy. AU - Zhang,G, AU - Wang,Y, AU - Zhang,Y, AU - Wan,X, AU - Li,J, AU - Liu,K, AU - Wang,F, AU - Liu,K, AU - Liu,Q, AU - Yang,C, AU - Yu,P, AU - Huang,Y, AU - Wang,S, AU - Jiang,P, AU - Qu,Z, AU - Luan,J, AU - Duan,H, AU - Zhang,L, AU - Hou,A, AU - Jin,S, AU - Hsieh,T-C, AU - Wu,E, PY - 2011/05/22/received PY - 2011/10/09/revised PY - 2011/10/10/accepted PY - 2012/1/28/entrez PY - 2012/1/28/pubmed PY - 2012/5/25/medline SP - 163 EP - 76 JF - Current molecular medicine JO - Curr. Mol. Med. VL - 12 IS - 2 N2 - The purpose of this study was to test the hypothesis that administration of epigallocatechin-3-gallate (EGCG), a polyphenol present in abundance in widely consumed tea, inhibits cell proliferation, invasion, and angiogenesis in breast cancer patients. EGCG in 400 mg capsules was orally administered three times daily to breast cancer patients undergoing treatment with radiotherapy. Parameters related to cell proliferation, invasion, and angiogenesis were analyzed while blood samples were collected at different time points to determine efficacy of the EGCG treatment. Compared to patients who received radiotherapy alone, those given radiotherapy plus EGCG for an extended time period (two to eight weeks) showed significantly lower serum levels of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and reduced activation of metalloproteinase-9 and metalloproteinase-2 (MMP9/MMP2). Addition of sera obtained from patients treated with combination of radiotherapy and EGCG feeding for 2-8 weeks to in vitro cultures of highly-metastatic human MDA-MB-231 breast cancer cells resulted in the following significant changes: (1) suppression of cell proliferation and invasion; (2) arrest of cell cycles at the G0/G1 phase; (3) reduction of activation of MMP9/MMP2, expressions of Bcl-2/Bax, c-Met receptor, NF-κB, and the phosphorylation of Akt. MDA-MB-231 cells exposed to 5-10 µM EGCG also showed significant augmentation of the apoptosis inducing effects of γ-radiation, concomitant with reduced NF-κB protein level and AKT phosphorylation. These results provide hitherto unreported evidence that EGCG potentiated efficacy of radiotherapy in breast cancer patients, and raise the possibility that this tea polyphenol has potential to be a therapeutic adjuvant against human metastatic breast cancer. SN - 1875-5666 UR - https://www.unboundmedicine.com/medline/citation/22280355/full_citation L2 - http://www.eurekaselect.com/76103/article DB - PRIME DP - Unbound Medicine ER -